Follow the Prostatype Genomics AB share price and the full insider trade history of the company, a listed issuer based in Finland. Shares are quoted on the FI market, under the supervision of FIN-FSA. Operating in the Health Care sector, Prostatype Genomics AB has recorded 9 public disclosures. Market capitalisation: €15.2m. The latest transaction was reported on 15 August 2026 (Purchase). Among the most active insiders: Michael Häggman. The full history is free.
9
Insider Decl.
n/a
Thresholds
€413,131
9 ops.
Buy Volume
n/a
n/a
Sell Volume
41Σ signal
Buys €413,131n/a Sells
Fundamental score
Ranked 25,210 of 29,064 companies
25.2
score / 100
Value
0
Quality
50
FCF yld-160%
Earn yld-191%
EV/EBITDA·
ROE-148%
Gross mgn100%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.